Glucocorticoids and mepolizumab in eosinophilic asthma.

Glucocorticoids and mepolizumab in eosinophilic asthma.

Bibliographic Details
Main Authors:	Bel, E, Ortega, H, Pavord, I
Format:	Journal article
Language:	English
Published:	Massachussetts Medical Society 2014

Similar Items

Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma.
by: Bel, E, et al.
Published: (2014)

Mepolizumab in refractory eosinophilic asthma.
by: Pavord, I, et al.
Published: (2010)

Mepolizumab, quality of life, and severe eosinophilic asthma.
by: Pavord, I
Published: (2017)

Mepolizumab treatment in patients with severe eosinophilic asthma.
by: Ortega, H, et al.
Published: (2014)

Mepolizumab and exacerbations of refractory eosinophilic asthma.
by: Haldar, P, et al.
Published: (2009)

Meta-analysis of asthma-related hospitalization in mepolizumab studies of severe eosinophilic asthma
by: Yancey, S, et al.
Published: (2016)

Blood eosinophil depletion with mepolizumab, benralizumab and prednisolone in eosinophilic asthma
by: Moran, AM, et al.
Published: (2020)

Mepolizumab for eosinophilic COPD
by: Sciurba, F, et al.
Published: (2018)

Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies.
by: Ortega, H, et al.
Published: (2016)

Mepolizumab and the response to oral prednisolone in patients with severe eosinophilic asthma
by: Shrimanker, R, et al.
Published: (2017)

Evaluation of potential continuation rules for mepolizumab treatment of severe eosinophilic asthma.
by: Gunsoy, N, et al.
Published: (2017)

Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial.
by: Pavord, I, et al.
Published: (2012)

Clinical characterisation of exacerbations of severe eosinophilic asthma occurring on mepolizumab and placebo
by: Howell, I, et al.
Published: (2024)

Characterisation of exacerbations of severe eosinophilic asthma (SEA) on mepolizumab compared to placebo
by: Shrimanker, R, et al.
Published: (2017)

Fractional exhaled nitric oxide and the peripheral blood eosinophil count as biomarkers of the response to mepolizumab in patients with severe eosinophilic asthma
by: Shrimanker, R, et al.
Published: (2018)

Depletion rate of blood eosinophils with mepolizumab, benralizumab and oral prednisolone in patients with severe asthma
by: Moran, A, et al.
Published: (2020)

Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: a 12-month follow-up analysis.
by: Haldar, P, et al.
Published: (2014)

Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: A 12-month follow-up analysis
by: Haldar, P, et al.
Published: (2014)

Mepolizumab for eosinophilic chronic obstructive pulmonary disease
by: Pavord, I, et al.
Published: (2017)

Biomarkers for severe eosinophilic asthma.
by: Yancey, S, et al.
Published: (2017)

Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: A 12-month follow-up analysis
by: Haldar, P, et al.
Published: (2014)

Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis
by: Wechsler, M, et al.
Published: (2017)

Eosinophil scRNAseq data from patients with asthma before and after mepolizumab treatment
by: Luo, J
Published: (2024)

Late breaking abstract - Dose-ranging study of mepolizumab in eosinophilic COPD
by: Pavord, I, et al.
Published: (2017)

Eosinophils in asthma and airway hyperresponsiveness.
by: Brightling, C, et al.
Published: (2004)

Exacerbations of severe asthma in patients treated with mepolizumab
by: Shrimanker, R, et al.
Published: (2018)

Non-eosinophilic asthma and the innate immune response.
by: Pavord, I
Published: (2007)

Non-eosinophilic corticosteroid unresponsive asthma.
by: Pavord, I, et al.
Published: (1999)

Eosinophils in asthma and other allergic diseases.
by: Wardlaw, A, et al.
Published: (2000)

The significance of eosinophilic airway inflammation in asthma
by: Pavord, I, et al.
Published: (2002)

Pathological features and inhaled corticosteroid response of eosinophilic and non-eosinophilic asthma.
by: Berry, M, et al.
Published: (2007)

Comparison of airway immunopathology of eosinophilic bronchitis and asthma.
by: Brightling, C, et al.
Published: (2003)

Occupational asthma due to low molecular weight agents: eosinophilic and non-eosinophilic variants.
by: Anees, W, et al.
Published: (2002)

Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease (COPD): A Meta-Analysis of METREX and METREO Exacerbation Endpoints
by: Bafadhel, M, et al.
Published: (2018)

IL-5 antagonism reverses priming and activation of eosinophils in severe eosinophilic asthma
by: Luo, J, et al.
Published: (2024)

Severe eosinophilic asthma: a roadmap to consensus.
by: Buhl, R, et al.
Published: (2017)

Eosinophils in Asthma and Airway Hyperresponsiveness [3] (multiple letters)
by: Brightling, C, et al.
Published: (2004)

Eosinophil protein in airway macrophages: a novel biomarker of eosinophilic inflammation in patients with asthma.
by: Kulkarni, N, et al.
Published: (2010)

Feno and blood eosinophils as biomarkers in predicting asthma exacerbations
by: Rastogi, S, et al.
Published: (2017)

A novel CT scoring system differentiates admissions secondary to eosinophilic from non-eosinophilic asthma
by: Hynes, G, et al.
Published: (2017)